Neurochemical markers of brain damage in cerebrospinal fluid during induction treatment of acute lymphoblastic leukemia in children

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 793-798

  Österlundh, Gustaf ^a,c   Kjellmer, Ingemar ^a   Lannering, Birgitta ^a   Rosengren, Lars ^a   Nilsson, Ulf A ^b   Márky, Ildikó ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Ascorbyl radical; Cerebrospinal fluid; Childhood acute lymphoblastic leukemia; Glial fibrillary acidic protein; Neurofilament protein; Neuron specific enolase

Indexed keywords

ASCORBIC ACID; ASPARAGINASE; DOXORUBICIN; GLIAL FIBRILLARY ACIDIC PROTEIN; METHOTREXATE; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN LIGHT CHAIN; NEURON SPECIFIC ENOLASE; PREDNISOLONE; RADICAL; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CHILD; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK FACTOR;

EID: 40449115063     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21378     Document Type: Article

References (32)

1. 1 Poplack DG, Brouwers P. Adverse sequelae of central nervous system therapy. Clin Oncol 1985 ; 4: 263–284.
2. 2 Meadows AT, Gordon J, Massari DJ, et al. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukemia treated with cranial irradiation. Lancet 1981 ; 318: 1015–1018.
3. 3 Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989 ; 11: 93–105.
4. 4 Schrappe M, Reiter A, Henze G, et al. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS‐directed chemotherapy in four consecutive ALL‐BFM trials. Klin Padiatr 1998 ; 210: 192–199.
5. 5 Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high‐dose methotrexate in the reduction of CNS irradiation. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Leukemia 2000 ; 14: 2267–2275.
6. 6 Jaffe N, Takaue Y, Anzai T, et al. Transient neurologic disturbances induced by high‐dose methotrexate treatment. Cancer 1985 ; 56: 1356–1360.
7. 7 Österlundh G, Bjure J, Lannering B, et al. Studies of cerebral blood flow in children with acute lymphoblastic leukemia: Case reports of six children treated with methotrexate examined by single photon emission computed tomography. J Pediatr Hematol Oncol 1997 ; 19: 28–34.
8. 8 Österlundh G, Bjure J, Lannering B, et al. Regional cerebral blood flow and neuron‐specific enolase in cerebrospinal fluid in children with acute lymphoblastic leukemia during induction treatment. J Pediatr Hematol Oncol 1999 ; 21: 378–383.
9. 9 Leviton A, Dammann O. Brain damage markers in children. Neurobiological and clinical aspects. Acta Paediatr 2002 ; 91: 9–13.
10. 10 Rosengren LE, Wikkelsø C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of adults. J Neurosci Methods 1994 ; 51: 197–204.
11. 11 Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996 ; 7: 267–272.
12. 12 Blennow M, Sävman K, Ilves P, et al. Brain‐specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr 2001 ; 90: 1171–1175.
13. 13 Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996 ; 67: 2013–2018.
14. 14 Teunissen CE, Dijkstra C, Palman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005 ; 4: 32–41.
15. 15 Buettner GR, Jurkiewicz BA. Ascorbate free radical as a marker of oxidative stress: An EPR study. Free Radic Biol Med 1993 ; 14: 49–55.
16. 16 Bayir H, Kagan VE, Tyurina YY, et al. Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Res 2002 ; 51: 571–578.
17. 17 Ogihara T, Hirano K, Ogihara H, et al. Non‐protein‐bound metals and hydroxyl radical generation in cerebrospinal fluid of newborn infants with hypoxic ischemic encephalopathy. Pediatr Res 2003 ; 53: 594–599.
18. 18 Welin AK, Sandberg M, Lindblom A, et al. White matter injury following prolonged free radical formation in the 0.65 gestation fetal sheep brain. Pediatr Res 2005 ; 58: 100–105.
19. 19 Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998 ; 87: 1151–1161.
20. 20 Saarinen‐Pihkala UM, Gustafsson G, Carlsen N, et al. Outcome of children with high‐risk acute lymphoblastic leukemia (HR‐ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer 2004 ; 42: 8–23.
21. 21 Påhlman S, Esscher T, Bergvall P, et al. Purification and characterization of human neuron‐specific enolase: Radioimmunoassay development. Tumour Biol 1984 ; 5: 127–139.
22. 22 Rosengren LE, Ahlsen G, Belfrage M, et al. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of children. J Neurosci Methods 1992 ; 44: 113–119.
23. 23 Bågenholm R, Nilsson UA, Kjellmer I. Formation of free radicals in hypoxic ischemic brain damage in the neonatal rat, assessed by an endogenous spin trap and lipid peroxidation. Brain Res 1997 ; 773: 132–138.
24. 24 Garca‐Alix A, Quero J. Brain‐specific proteins as predictors of outcome in asphyxiated term infants. Acta Paediatr 2001 ; 90: 1103–1105.
25. 25 Dotevall L, Hagberg L, Karlsson JE, et al. Astroglial and neuronal proteins in cerebrospinal fluid as markers of CNS involvement in Lyme neuroborreliosis. Eur J Neurol 1999 ; 6: 169–178.
26. 26 Verbeek MM, de Jong D, Kremer HPH. Brain‐specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003 ; 40: 25–40.
27. 27 Rosén H, Karlsson JE, Rosengren L. CSF levels of neurofilament is a valuable predictor of long‐term outcome after cardiac arrest. J Neurol Sci 2004 ; 221: 19–24.
28. 28 Nylén K, Csajbok LZ, Öst M, et al. CSF‐Neurofilament correlates with outcome after aneurysmal subarachnoid haemorrhage. Neurosci Lett 2006 ; 404: 132–136.
29. 29 Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006 ; 63: 1277–1280.
30. 30 Gisslén M, Rosengren L, Hagberg L, et al. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV‐1 infection. AIDS Res Ther 2005 ; 2: 6.
31. 31 Hurwitz RL, Mahoney DH, Armstrong DL, et al. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988 ; 16: 216–219.
32. 32 Bentson J, Reza M, Winter J, et al. Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr 1978 ; 2: 16–23.